Epigenomics AG (EPGNF)
OTCMKTS · Delayed Price · Currency is USD
1.120
+0.170 (17.89%)
At close: Jul 18, 2025
Epigenomics AG Revenue
Epigenomics AG had revenue of 4.00K EUR in the half year ending June 30, 2025, a decrease of -98.03%. This brings the company's revenue in the last twelve months to 4.00K, down -97.06% year-over-year.
Revenue (ttm)
4.00K EUR
Revenue Growth
-97.06%
P/S Ratio
187.98
Revenue / Employee
2.00K EUR
Employees
2
Market Cap
883.11K USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | 339.00K | -560.00K | -62.29% |
Dec 31, 2022 | 899.00K | -5.30M | -85.51% |
Dec 31, 2021 | 6.20M | 5.36M | 636.70% |
Dec 31, 2020 | 842.00K | -283.00K | -25.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 206.83M |
Elite Pharmaceuticals | 84.04M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
BioStem Technologies | 332.45M |